These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 32197799)
1. Patient reported outcomes as emerging biomarkers in chronic liver disease research. Verma M J Hepatol; 2020 Jun; 72(6):1215-1216. PubMed ID: 32197799 [No Abstract] [Full Text] [Related]
2. Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents. Giuffrè M; Masutti F; Maria Crosato I; Luzzati R; Saveria Crocè L Turk J Gastroenterol; 2022 Feb; 33(2):169-170. PubMed ID: 35238783 [No Abstract] [Full Text] [Related]
3. Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C? Lok AS Clin Infect Dis; 2021 Mar; 72(5):787-788. PubMed ID: 32052046 [No Abstract] [Full Text] [Related]
4. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. Saleh SA; Salama MM; Alhusseini MM; Mohamed GA World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761 [TBL] [Abstract][Full Text] [Related]
5. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case. Spooner LM; Abraham GM Am J Health Syst Pharm; 2017 Apr; 74(8):555. PubMed ID: 28389452 [No Abstract] [Full Text] [Related]
6. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974 [TBL] [Abstract][Full Text] [Related]
7. Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens. VanOpdorp JR; Ferrentino N; Strader DB; Lidofsky SD J Viral Hepat; 2019 Jun; 26(6):778-781. PubMed ID: 30801878 [No Abstract] [Full Text] [Related]
8. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. Bashir MH; Fazili J; Madhoun MF; Kanagala R; Chen S; Nusrat S Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):296-301. PubMed ID: 29200006 [TBL] [Abstract][Full Text] [Related]
9. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. del Valle J; Mira JA; de los Santos I; López-Cortés LF; Merino D; Rivero A; Girón JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Pineda JA AIDS; 2008 May; 22(8):923-30. PubMed ID: 18453851 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gonzalez HC; Gordon SC Gastroenterol Clin North Am; 2020 Jun; 49(2):301-314. PubMed ID: 32389364 [TBL] [Abstract][Full Text] [Related]
11. Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series. Childs-Kean LM; Hong J Gastroenterology; 2017 Oct; 153(4):1165-1166. PubMed ID: 28881195 [No Abstract] [Full Text] [Related]
12. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals. Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827 [TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. Spadaccini M; Lleo A; Ceriani R; Covini G; Rimassa L; Torzilli G; Di Tommaso L; Aghemo A Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):570-574. PubMed ID: 30420319 [No Abstract] [Full Text] [Related]
14. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Jacobson IM; Lim JK; Fried MW Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022 [TBL] [Abstract][Full Text] [Related]
15. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Vitrone M; Andini R; Mattucci I; Maiello C; Atripaldi L; Durante-Mangoni E; Zampino R Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29139181 [TBL] [Abstract][Full Text] [Related]
16. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts? Mondelli MU J Hepatol; 2004 Mar; 40(3):536-8. PubMed ID: 15123372 [No Abstract] [Full Text] [Related]
17. Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C. Higashi N; Nakamuta M; Motomura K; Enjoji M; Sakai H; Nawata H J Hepatol; 1999 Aug; 31(2):383. PubMed ID: 10453958 [No Abstract] [Full Text] [Related]
18. Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients. Gevers TJ; Burger D; Schipper-Reintjes E; Kooistra MP; Richter C Neth J Med; 2016 Jun; 74(5):225-7. PubMed ID: 27323683 [No Abstract] [Full Text] [Related]